Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods

Cancer Research

Volumn 65, Issue 21, 2005, Pages 10104-10112

  Kenny, Laura M ^a   Vigushin, David M ^a   Al Nahhas, Adil ^a   Osman, Safiye ^a   Luthra, Sajinder K ^a   Shousha, Sami ^b   Coombes, R Charles ^a   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; 3' FLUOROTHYMIDINE F 18; FLUORINE 18; KI 67 ANTIGEN; THYMIDINE KINASE; TRACER; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG UPTAKE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LABELING INDEX; METHODOLOGY; PARAMETER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; SPECTROSCOPY; TUMOR BIOPSY;

BREAST NEOPLASMS; CELL GROWTH PROCESSES; DIDEOXYNUCLEOSIDES; FLUORINE RADIOISOTOPES; HUMANS; KI-67 ANTIGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 27544449023     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4297     Document Type: Article

References (41)

1. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003; 63:6523-31.
2. Ellis MJ, Rosen E, Dressman H, Marks J. Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on treatment effect. J Steroid Biochem Mol Biol 2003;86: 301-7.
3. Giordano SH. Update on locally advanced breast cancer. Oncologist 2003;8:521-30.
4. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003;39:462-8.
5. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004;57:675-81.
6. Vincent-Salomon A, Rousseau A, Jouve M, et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 2004;40:1502-8.
7. Aboagye EO, Price PM. Use of positron emission tomography in anticancer drug development. Invest New Drugs 2003;21:169-81.
8. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7.
9. He Q, Mao Y, Wu J, et al. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol 2004;25:945-53.
10. 1-S-phase-regulated region in the human thymidine kinase gene promoter. Mol Cell Biol 1990;10:3834-7.
11. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988;263: 8350-8.
12. Sherley JL, Kelly TJ. Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells. J Biol Chem 1988;263:375-82.
13. Adler R, McAuslan BR. Expression of thymidine kinase variants is a function of the replicative state of cells. Cell 1974;2:113-7.
14. Toyohara J, Wald A, Takamatsu S, Yonekura Y, Magata Y, Fujibayashi Y. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29:281-7.
15. Li CL, Lu CY, Ke PY, Chang ZF. Perturbation of ATP-induced tetramerization of human cytosolic thymidine kinase by substitution of serine-13 with aspartic acid at the mitotic phosphorylation site. Biochem Biophys Res Commun 2004;313:587-93.
16. Kauffman MG, Kelly TJ. Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell Biol 1991;11:2538-46.
17. Chang ZF, Huang DY, Hsue NC. Differential phosphorylation of human thymidine kinase in proliferating and M phase-arrested human cells. J Biol Chem 1994; 269:21249-54.
18. Sutterluety H, Bartl S, Doetzlhofer A, Khier H, Wintersberger E, Seiser C. Growth-regulated antisense transcription of the mouse thymidine kinase gene. Nucleic Acids Res 1998;26:4989-95.
19. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995;35:69-89.
20. Barthel H, Perumal M, Latigo J, et al. The uptake of 3′-deoxy- 3′-[(18)F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005;32:257-63.
21. Barthel H, Cleij MC, Collingridge DR, et al. 3′-deoxy-3′- [18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63: 3791-8.
22. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65: 4202-10.
23. Buck AK, Schirrmeister H, Hetzel M, et al. 3-Deoxy-3-[(18)F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-4.
24. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003;44:1426-31.
25. Vesselle H, Grierson J, Muzi M, et al. In vivo Validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8: 3315-23.
26. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003;52: 1602-6.
27. Wagner M, Seitz U, Buck A, et al. 3′-[18F]Fluoro-3′- deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003;63:2681-7.
28. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
29. Cleij MC, Steel CJ, Brady F, Ell PJ, Pike VW, Luthra SK. An improved synthesis of 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) and the fate of the precursor 2,3′-anhydro-5′-O-(4,4′-dimethoxytrityl) -thymidine. J Labelled Compounds Radiopharm 2001;44:871-3.
30. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46:274-82,
31. Herholz K, Patlak CS. The influence of tissue heterogeneity on results of fitting nonlinear model equations to regional tracer uptake curves: with an application to compartmental models used in positron emission tomography. J Cereb Blood Flow Metab 1987;7: 214-29.
32. Mankoff DA, Shields AF, Graham MM, Link JM, Krohn KA. A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. J Nucl Med 1996;37:2049-57.
33. Schmidt K, Lucignani G, Moresco RM, et al. Errors introduced by tissue heterogeneity in estimation of local cerebral glucose utilization with current kinetic models of the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab 1992;12:823-34,
34. Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993;13: 15-23.
35. Meikle SR, Matthews JC, Brock CS, et al. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother Pharmacol 1998;42: 183-93.
36. Shields AF, Grierson JR, Muzik O, et al. Kinetics of 3′-deoxy- 3′-[F-18]fluorothymidine uptake and retention in dogs. Mol Imaging Biol 2002;4:83-9.
37. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992;52:1592-7.
38. Visvikis D, Francis D, Mulligan R, et al. Comparison of methodologies for the in vivo assessment of (18)FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 2004;31:169-78.
39. Smyczek-Gargya B, Fersis N, Dittmann H, et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004; 31:720-4.
40. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-50.
41. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999;213:521-5.